UK nanomedicine projects awarded £6.5m funding
2 March 2012
Grant funding totalling over £6.5 million has been awarded for
seven business-led projects that will focus on developing therapeutic
agents and diagnostics where nanoscale technologies are at the heart of
The funding will be provided by the UK Engineering and Physical
Sciences Research Council (EPSRC) and the Technology Strategy Board
and the projects will be led by Critical Pharmaceuticals Ltd,
Johnson Matthey plc, Mologic Ltd, Nanomerics Ltd, OJ-Bio Ltd,
Renishaw Diagnostics Ltd and Sharp Laboratories of Europe Ltd.
The aim of the investment is to help ensure that the UK can
become an early competitive adopter of these novel technologies and
rapidly meet the urgent and difficult challenges posed within the
worldwide healthcare sector, by translating world-class early stage
ideas from academia and commercialising them through building supply
chains with innovative businesses.
This investment is part of a two stage initiative under the
Nanoscience through Engineering to Application Grand Challenge for
Healthcare. The University partners on two of the funded projects
had initially received 3 years of funding from EPSRC and these
projects will follow on seamlessly to scale-up the technologies
developed in the first stage.
EPSRC Chief Executive, David Delpy, said: “This is the second
example of pulling nanoscience research originally funded by the
Research Councils through to application by co-funding with the
Technology Strategy Board. This approach actively supports economic
growth whilst contributing to advances in healthcare technologies."
Iain Gray, Chief Executive of the Technology Strategy Board,
said: “Nanoscale technologies are at the heart of the innovations
that will be developed through these seven interesting and exciting
projects. They will address challenges in building the supply chain
across enabling nanoscale technologies and the healthcare sector,
and take ideas from basic proof-of-concept or process to pilot
The new research and development projects will help to develop
links between the healthcare community and the emerging nanoscale
technologies community, in order to rapidly develop and
commercialise early-stage nanoscale technologies.
Key challenge areas include the earlier and better detection and
diagnosis of disease, leading to marked improvements in patient
outcomes, and highly effective treatments that are tailored to
patients’ needs, and which either modify the underlying disease or
offer potential cures.
For a full list of the projects see: NanoscaleTEH projects: